Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-05-24
2005-05-24
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388850, C530S388230, C530S387300, C424S001110
Reexamination Certificate
active
06896885
ABSTRACT:
The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies.The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).
REFERENCES:
patent: 5231012 (1993-07-01), Mossman et al.
patent: 5286850 (1994-02-01), Gansow
patent: 5595721 (1997-01-01), Kaminski
patent: 5639600 (1997-06-01), McGrath
patent: 5677180 (1997-10-01), Robinson
patent: 5716612 (1998-02-01), Rybak
patent: 5736137 (1998-04-01), Anderson
patent: 5770190 (1998-06-01), Bruserud et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5837232 (1998-11-01), DeWaal Malefyt et al.
patent: 5837293 (1998-11-01), De Waal Malefyt
patent: 5863796 (1999-01-01), Moore et al.
patent: 5871725 (1999-02-01), Schwarz
patent: 6090365 (2000-07-01), Kaminski
patent: 6106823 (2000-08-01), Vierira et al.
patent: 6113898 (2000-09-01), Anderson
patent: 6183744 (2001-02-01), Goldenberg
patent: 6207154 (2001-03-01), Mossman et al.
patent: 6217857 (2001-04-01), Mossman et al.
patent: 6239260 (2001-05-01), Mossman et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6319493 (2001-11-01), Vierira et al.
patent: 6423500 (2002-07-01), Moore et al.
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 20020012665 (2002-01-01), Hanna
patent: 295 12 719 (1996-08-01), None
patent: 0567450 (1999-06-01), None
patent: WO 94 04180 (1994-03-01), None
patent: WO 9503411 (1995-02-01), None
patent: WO9856418 (1998-12-01), None
patent: WO0020864 (2000-04-01), None
Paul., Fundamental Immunology, chapter 8, Raven Press, NY, p. 242, 1993.*
Levy et al., J. Clin. Invest 93:424-428, 1994.*
Alas et al ., Blood vol. 92, No. 10 Suppl. 1 part 1-2, pp 601A, 1998.*
Czuczman et al., “Treatment of Patients with Low-Grade B-Cell Lymphoma . . . ” Journal of Clinical Oncology, Jan. 1999, vol. 17, No. 1, Philadelphia, PA.
Demidem Aicha et al., “Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody sensitizes a B-cell..” Cancer Biotherapy & Radiopharmaceuticals, 1997, pp. 177-186, vol. 12, No. 3.
Buske, C. et al., “Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphmas: Emerging . . . ” European Journal of Cancer, Pergamon Press, 1999, pp. 549-557, Oxford GB.
Cortes, J. et al., “Interleukin-10 in Non-Hodgkin's Lymphoma” Leukemia and Lymphoma, Harwood Academic Publishers, Jul. 1997, vol. 26, No. 3/4 pp. 251-259, Chur, CH.
Levy, Y. et al., “Interleuken-10 Prevent Spontaneious Death of Germinal Center B Cells by Induction of the B Cells by Induction of the bcl-2 Protein”, J. Cin. Inves. vol. 93 (Jan. 1994) pp. 424-428.
Alas, S. et al., Chimeric Anti-CD20(C2B8)-Mediated Sensitization of B Cell Lymphoma to Cytotoxic Agents: Role of C2B8 . . . , Abstract#2479, Blood (No. 15, 1998) vol. 92, Supp. Pat1-2, pp. 601A.
Berzofsky, J. et al. , “Fundamental Immunology”, Ch. 8, p. 242, (1993), Ed. William E. Paul.—Immunogencicity and Antigen Structure.
Bonnefoix et al., “Growth Modulation of Freshly Isolated Non-Hodgkin's B- Lymphoma Cells Induced by Various Cytokines and All-Trans-Retinoic-Acid,”Leukemia and Lymphoma,25:169-178.
Beatty PR et al., “Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines,”J Immunol,1997, 158: 4045-4051.
Bonavida B et al., “Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells,”Gynecol Oncol,1990, 38: 333-339.
Cortes J et al., “Interleukin-10 in non-Hodgkin's lymphoma,”Leuk Lymphoma,1997, 26: 251-9.
Dedoussis GV et al., “Endogenous interleukin 6 conveys resistance to cis- diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line,”Exp Cell Res,1999, 249: 269-278.
Hekman A et al., “Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody,”Cancer Immunol Immunother,1991, 32: 364-372.
Kiesel S et al., “Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis,”Leuk Res,1987, 11: 1119-1125.
Mosmann TR et al., “Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2- specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay,”J Immunol,1990, 145: 2938-2945.
Press OW et al., “Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas,”Blood,1987, 69: 584-591.
Stasi R et al., “Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma,”Eur J Haematol,1995, 54: 9-17.
Vlasveld LT et al., “Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB- CD19,”Cancer Immunol Immunother,1995, 40: 37-47.
Voorzanger N et al., “Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors,”Cancer Res,1996, 56: 5499-5505.
Wang Z et al., “Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo,”Int J Cancer,1996, 68: 583-587.
Yonish-Rouach E et al., “Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6,”Nature,1991, 352: 345-347.
Idec Pharmaceuticals and Corixa Corp.,Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
Biogen Idec v. Corixa Corp.,Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
Kaminski, et al., “Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody,” 1990,Antibody Immunoconjugates, and Radiopharmaceuticals,vol. 3, No. 1, Abstract No. 83.
Kaminski, et al., “Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody,” 1990,Proceedings of ASCO,vol. 9, p. 271, Abstract No. 1051.
Wahl, et al., “RadioImmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody,”The Journal of Nuclear Medicine: Proceedings of the 37thAnnual Meeting,p. 852, Abstract No. 622.
Kaminski, et al., “Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma,” 1990,Antibody Immunoconjugates, and Radiopharmaceuticals,vol. 4, No. 1, p. 36, Abstract No. 66.
Kaminski, et al., “Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma,” 1990,Blood,vol. 76, No. 10, p. 355a, Abstract No. 1409.
Kaminski, et al., “Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma,” 1992,Journal of Clinical Oncology,vol. 10, No. 11, pp. 1696-1711.
Jensen, et al., “Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab),” 1998,Ann Hematol,vol. 77, pp. 89-91.
Biogen Idec Inc.
Helms Larry R.
Pillsbury & Winthrop LLP
LandOfFree
Combined use of anti-cytokine antibodies or antagonists and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined use of anti-cytokine antibodies or antagonists and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined use of anti-cytokine antibodies or antagonists and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446405